Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
Glucagon-like peptide-1 (GLP-1) receptor agonists have moved decisively beyond diabetes care, emerging as multimodal therapeutics with broad relevance across neurology. Their potent effects on weight, vascular function, inflammation...
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an increasingly popular class of medications commonly used for glycemic control in patients with type 2 diabetes mellitus and for weight loss.
Ozempic was developed by Novo Nordisk as a GLP-1 receptor agonist, meaning it mimics the action of a natural hormone that helps regulate blood sugar and appetite. It was approved by the FDA in 2017 as a treatment for type 2 diabetes.
Stefanou MI, Palaiodimou L, Theodorou A et al (2024) Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP1 RAs or the dual GIP/GLP1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and...
2026 Google LLC.
Tirzepatide is a GIP and GLP-1 receptor agonist. Tirzepatide is self-administered as a subcutaneous injection using a single-dose pen, multi-dose KwikPen, or a vial with a syringe, and should always be used alongside a healthy diet and regular exercise.
